<?xml version="1.0"?>

<document>
	<title>Complement in cystic fibrosis.</title>

	<author>Strauss-R-G.</author>

	<source>Helv-Paediatr-Acta. 1979. 34(5). P 429-35.</source>

	<abstract>Quantitative and functional assessments were made of both the
   classical and alternative pathways of complement activation in sera
   from 23 patients with cystic fibrosis. The classical pathway
   functioned similarly in patients and controls as measured by CH50
   titre. Alternative pathway function, initiated in patient sera by
   incubation with inulin, was equal to that of controls as determined
   by cleavage of Factor B and C3, and by the consumption of terminal
   components. Factor B, however, was more readily activated in patient
   than in control sera. This rapid alteration of Factor B did not lead
   to accelerated or more extensive activation of the terminal
   complement components via the alternative pathway when assessed by C3
   cleavage and the consumption of terminal components. Thus, a
   complement deficiency was not found. The importance of the easily
   activated Factor B is undefined.</abstract>

	<majorsubject>COMPLEMENT-3: an</majorsubject>
	<majorsubject>CYSTIC-FIBROSIS: im</majorsubject>

	<minorsubject>ADOLESCENCE</minorsubject>
	<minorsubject>ADULT</minorsubject>
	<minorsubject>CHILD</minorsubject>
	<minorsubject>CHILD-PRESCHOOL</minorsubject>
	<minorsubject>COMPLEMENT-PATHWAY-ALTERNATIVE</minorsubject>
	<minorsubject>COMPLEMENT-PATHWAY-CLASSICAL</minorsubject>
	<minorsubject>COMPLEMENT-3B-INACTIVATORS: an</minorsubject>
	<minorsubject>HUMAN</minorsubject>
	<minorsubject>INULIN: du</minorsubject>

	<reference>001   BOWMAN BH             BIOCHEM BIOPHYS RES COMMUN      64  1310 975</reference>
	<reference>002   BUESCHER ES           J PEDIATR                       93   530 978</reference>
	<reference>003   CONOVER JH            LANCET                           2  1501 973</reference>
	<reference>004   CONOVER JH            TEX REP BIOL MED                34    45 976</reference>
	<reference>005   FORRISTAL J           CLIN EXP IMMUNOL                23    61 977</reference>
	<reference>006   GOTZ M                EUR J PEDIATR                  127   133 978</reference>
	<reference>007   GOTZE O               J EXP MED                      134   90S 971</reference>
	<reference>008   HOLZHAUER RJ          PEDIATR RES                     10   365 976</reference>
	<reference>009   HANN S                LANCET                           2   520 974</reference>
	<reference>010   KABAT EA              EXPERIMENTAL IMMUNOCHEMISTRY             961</reference>
	<reference>011   LIEBERMAN J           AM REV RESPIR DIS              111   100 975</reference>
	<reference>012   LYRENE RK             J PEDIATR                       91   681 977</reference>
	<reference>013   POLLEY MJ             J MED GENET                     11   249 974</reference>
	<reference>014   SCANLIN TF JR         LANCET                           1  1382 974</reference>
	<reference>015   SCHIOTZ PO            ACTA PATH MICROBIOL SCAND (C)   86    37 978</reference>
	<reference>016   STRAUSS RG            PEDIATR RES                     11   285 977</reference>
	<reference>017   STRUNK RC             ARCH DIS CHILD                  52   687 977</reference>
	<reference>018   WEST CD               J IMMUNOL                       96   650 966</reference>
	<reference>019   WILSON GB             J LAB CLIN MED                  92   463 978</reference>

	<citation>1   SPEERT DP             SURV SYNTH PATHOL RES            4    14 985</citation>

</document>
